Oxford researchers are currently working with Moderna and Astra Zeneca to find a vaccine for the Coronavirus pandemic. The trial, which started in April, involved roughly 1,000 people, half of whom got the cure. Participants who got the vaccine developed neutralizing antibodies, which researchers believe are important for protecting against the virus.
While there is still more work to be done, the current research data increases the confidence that the vaccine will work and therefore they continue their plans to manufacture the cure at scale for broad and equitable access around the world.
Coronavirus Vaccine made by Oxford and Moderna
Moderna announced last week that the vaccine will begin its largest study, involving 30,000 people, on July 27. It is expected to be the first U.S. vaccine to enter phase three trials. In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months after they were immunized.
Adrian Hill, the director of Oxford university’s Jenner Institute, said early projections that a million doses of the cure could be made by September could be an under-estimate, depending on how quickly late-stage trials can be completed. Oxford researchers have been working on the ChAdOx1 nCoV-19 cure for a long time now. The upcoming trials will help us understand the effectiveness of the cure. Human trials are still not going on at a mass level, therefore, it is not sure if the cure will be able to treat the majority of world population.
Researchers say the proposed cure can cause minor side effects more frequently than a control group, but some of these can be reduced by taking paracetamol. Let us know what you have to say about this in the comments section below! Also, don’t forget to join us on our Telegram Channel for more such latest updates and discussions.
Suryapratim Ray is an engineer, author, robotics hobbyist, and an active Quoran. Being a technical blogger, he covers the good, bad, and ugly of science on a regular basis at Sciencenews18. In addition to his passion for writing, he’s equally keen on learning classical music.